PBE vs XBI

Key Takeaways

• PBE follows a rules-based, tiered equal-weighted index focused on biotechnology and genome companies, resulting in a concentrated portfolio of approximately 33 holdings.
• XBI tracks an equal-weighted S&P Biotechnology Select Industry Index, providing broader diversification across roughly 130–150 holdings.
• PBE carries a higher expense ratio of 0.58% compared with XBI’s 0.35%, reflecting differences in index construction and management approach.
• Both ETFs deliver pure-play exposure to the U.S. biotechnology sector, with 100% allocation to healthcare, but differ in concentration risk and rebalancing frequency.
• XBI’s equal-weight methodology reduces single-stock risk relative to PBE’s more concentrated top holdings.
• Structural differences position the funds as complementary rather than direct competitors for investors seeking biotech exposure with varying risk and cost profiles.

Introduction

Investors evaluating targeted biotechnology exposure often compare PBE and XBI because both provide dedicated access to U.S. biotech companies. While they operate in the same sector, the ETFs employ distinct index methodologies—one rules-based and concentrated, the other equal-weighted and diversified—offering alternative approaches to similar investment objectives. This comparison highlights structural differences that influence risk, cost, and positioning within the broader healthcare thematic landscape.

Invesco Biotechnology & Genome ETF (PBE) Overview

The Invesco Biotechnology & Genome ETF tracks the Dynamic Biotech & Genome Intellidex Index, a rules-based, tiered equal-weighted benchmark of U.S. companies engaged in biotechnology research, development, and genome-related activities. The fund typically holds around 33 securities and maintains a 100% allocation to the healthcare sector. Top holdings generally include names such as Regeneron Pharmaceuticals, Amgen, and Vertex Pharmaceuticals, each representing approximately 5% of assets. PBE uses a passive, rules-driven strategy with periodic rebalancing to maintain index alignment. Its expense ratio stands at 0.58%. The structure emphasizes companies with strong fundamentals in biotech innovation while limiting exposure to any single issuer through tiered weighting.

SPDR S&P Biotech ETF (XBI) Overview

The SPDR S&P Biotech ETF seeks to replicate the performance of the S&P Biotechnology Select Industry Index, an equal-weighted index drawn from the biotechnology segment of the S&P Total Market Index. The fund holds approximately 130–150 stocks and allocates 100% of assets to healthcare, specifically biotechnology. Because of its equal-weight methodology, top holdings typically represent 1–3% of the portfolio each, promoting broader diversification across market-capitalization segments. XBI employs a passive strategy with quarterly rebalancing to maintain equal weights. Its expense ratio is 0.35%. The design reduces concentration risk relative to more top-heavy peers while capturing a wide spectrum of biotech innovators.

Industry and Thematic Backdrop

The biotechnology sector continues to benefit from long-term innovation in gene editing, personalized medicine, and novel therapeutics, supported by ongoing research and development pipelines. Macroeconomic factors such as interest-rate expectations and capital availability influence funding for early-stage companies. Regulatory developments around drug approvals and intellectual-property protections remain key catalysts. Sector risks include clinical-trial failures, pricing pressures, and shifts in healthcare policy. Capital flows into biotech have shown resilience across recent market cycles, driven by both large-cap stability and small-cap innovation potential.

Performance and Positioning Comparison

Over recent weeks and months, relative performance between the two ETFs has reflected differences in concentration and weighting. PBE’s more concentrated holdings can amplify moves tied to earnings or clinical milestones of its largest positions. XBI’s equal-weight approach has historically provided smoother participation across the sector during periods of broad biotech rotation. Volatility differences arise from portfolio construction: PBE tends to exhibit higher sensitivity to individual stock events, while XBI offers more balanced exposure that may moderate extreme swings. Both funds respond to sector-wide drivers such as earnings cycles, regulatory news, and macroeconomic shifts affecting healthcare investment sentiment.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking biotech exposure can leverage the platform to compare holdings, sector allocations, and technical characteristics across funds like PBE and XBI.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a modest edge to XBI. Its lower expense ratio, broader diversification through equal weighting, and reduced concentration risk align with favorable cost-efficiency and risk-management metrics. PBE offers a more targeted, rules-based approach that may appeal to investors prioritizing specific genome-focused themes, yet XBI’s profile demonstrates stronger overall positioning across cost, diversification, and liquidity dimensions in the current environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations